SEC Form 4 · accession 0001179110-18-010332
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dimitrios Chondros
Officer — SVP, Chief Medical Officer
Period of report
Aug 3, 2018
Accepted (ET)
Aug 6, 2018 · 6:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001159036
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 3, 2018 | F | 1,305 | $17.08 | D | 34,102 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported disposition of 1,305 shares represents the shares that were withheld by the issuer as payment for minimum statutory obligations due upon vesting of 3,750 restricted stock award shares.